EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension


Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension



British Journal of Clinical Pharmacology 24(6): 721-727



ISSN/ISBN: 0306-5251

PMID: 2894216

DOI: 10.1111/j.1365-2125.1987.tb03237.x

1. The effects of fenoldopam, an orally active, specific dopamine-1 receptor agonist, were studied in eleven patients with essential hypertension, using intra-arterial blood pressure recording and equilibrium gated radionuclide angiography. 2. A single dose of fenoldopam 100 mg produced a fall in blood pressure (BP) starting after 20 min. The maximum BP reduction (23/25 mm Hg) occurred after 50 min and was accompanied by a heart rate (HR) increase of 10 beats min-1. The acute effects on BP lasted for 130 min. 3. After 8 weeks of fenoldopam 100 mg, twice daily, only a small, statistically insignificant, hypotensive effect was still apparent after each dose of drug. The duration of the effect was too short to be clinically useful. Tilt-testing produced a BP fall of 24/14 mm Hg and a HR increase of 17 beats min-1. Three patients experienced symptoms of postural hypotension during the study. 4. The drug attenuated the blood pressure rise produced by dynamic cycle exercise and isometric hand grip. 5. Acute administration of fenoldopam increased the left ventricular ejection fraction from 61% to 71% (P < 0.005) and increased the peak filling rate from 2.52 to 3.86 end diastolic vol s-1 (P < 0.002). After chronic fenoldopam administration, the left ventricular ejection fraction was 65% (P = NS) pre-dose, rising to 69% (P < 0.02) post-dose and the peak filling rate was increased from 2.7 to 3.38 end diastolic vol s-1 (P < 0.01) 60 min post-dose. There was also a significant increase of the first one-third filling fraction from 0.24 to 0.47 (P < 0.01) pre-dose, indicating improved diastolic function. 6. Although the duration of action of this formulation of fenoldopam is too short to recommend it for clinical use, a slow-release preparation would merit further investigation for treatment of hypertension and heart failure.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 005304065

Download citation: RISBibTeXText

Related references

The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. British Journal of Clinical Pharmacology 19(1): 21-27, 1985

Fenoldopam a specific dopamine receptor agonist in severe hypertension. Journal of Clinical Pharmacology 28(10): 930, 1988

The effects of a Dopamine Agonist, Fenoldopam, on LV Function in Hypertension. Clinical Science 71(S15): 17p.2-17p, 1986

Effects of the selective dopamine 1 receptor agonist fenoldopam on blood pressure and noradrenaline release in pithed rabbits with electrically stimulated sympathetic outflow. Naunyn Schmiedeberg'S Archives Of Pharmacologyuppl: R80, 1986

Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 69(6): 1142-1145, 1984

Effects of a dopamine da 1 receptor agonist fenoldopam on human intraocular pressure. Investigative Ophthalmology and Visual Science 68(3 Suppl.): 66, 1987

Effects of long-acting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. American Journal of Cardiology 70(4): 474-478, 1992

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Critical Care Medicine 27(9): 1832-1837, 1999

Effects of the selective dopamine da 1 receptor agonist fenoldopam on renal function in the anesthetized dog. British Journal of Pharmacology 95(Suppl.): 858P, 1988

Dose response analysis of the effects of fenoldopam a dopamine 1 receptor agonist on renal function. Drug Development Research 22(1): 59-68, 1991

Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. American Journal of Cardiology 69(9): 918-922, 1992

Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. British Journal of Clinical Pharmacology 21(1): 53-61, 1986

Selective dopamine-1 receptor agonist augments regional myocardial blood flow: comparison of fenoldopam and dopamine. American Heart Journal 124(2): 418-423, 1992

Comparative effects of intravenous fenoldopam and nitroprusside on left ventricular systolic and diastolic function in severe hypertension. Clinical Research 38(1): 26A, 1990

Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. New England Journal of Medicine 345(21): 1548-1557, 2001